All In Biotech

Drug Trial Radar · NCT02117401

A Prospective, Multi-center, Randomized Controlled Study of Muscle Relaxation Effect and Safety of Mivacurium Chloride in Pediatric Surgery Patients

A Prospective, Multi-center, Randomized Controlled Study of Neuromuscular Blocking Effect and Safety of Mivacurium Chloride in Pediatric Patients

Last checked: Nov 19, 2026Latest source record: Jul 15, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,152 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,152

Actual

Start

Jan 2012

Primary completion

Jun 2013

Study completion Jun 2013

Sponsor

Sponsor type
Industry
First posted
Apr 21, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 2 months, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the effect and safety of mivacurium chloride in pediatric patients.

Conditions

  • Efficacy and Safety of Mivacurium Chloride for Pediatric Patients

Interventions

  • mivacurium chlorideDrug

    intravenously injected during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.

  • midazolamDrug

    Before induction: after moving into operating room, oral administration with dose of 0.5 mg/kg or mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg

  • ketamineDrug

    mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg

  • propofolDrug

    Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min

  • RemifentanilDrug

    Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. intubation scoreTime frame: 1 minute within intubation
  2. muscle relaxation effectTime frame: from baseline to no more than 120 minutes after intubation

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.